Use of octreotide in the acute management of bleeding esophageal varices

Canadian Journal of Gastroenterology

Volumn 11, Issue 4, 1997, Pages 339-343

  Sadowski, Daniel C ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bleeding esophageal varices; Octreotide

Indexed keywords

OCTREOTIDE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE;

ARTICLE; DRUG COST; DRUG EFFICACY; EARLY DIAGNOSIS; ENDOSCOPIC SURGERY; ESOPHAGUS VARICES BLEEDING; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIGATION; LIVER CIRRHOSIS; MORTALITY; PORTAL VEIN; PRIORITY JOURNAL;

EID: 0030912426     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/1997/156920     Document Type: Article

References (13)

1. Graham DY, Smith JL. The course of patients after variceal hemorrhage. N Engl J Med 1981;80:800-9.
2. Gullo L, Billotti G, Pezzilli R, Di Stefano M, Ancona D. Effect of octreotide (SMS 201-995) on meal-stimulated pancreatic secretion in three patients with external pancreatic fistula. Am J Gastroenterol 1991;86:892-4.
3. Creutzfeldt W, Lembcke B, Folsch UR, Schleser S, Koop I. Effect of somatostatin analogue (SMS 201-995, Sandostatin) on pancreatic secretion in humans. Am J Med 1987;82:49-54.
4. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133-40.
5. Del Pozo E, Neufeld M, Schluter K, et al. Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol (Copenh) 1986;111:433-9.
6. Eriksson LS, Brundin T, Soderlund C, Wahren J. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol 1987;22:919-25.
7. Pringle SD, McKee RF, Garden OJ, Lorimer AR, Carter DC. The effect of a long-acting somatostatin analogue on portal and systemic haemodynamics in cirrhosis. Aliment Pharmacol Ther 1988;2:451-9.
8. Albillos A, Rossi I, Iborra J, et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994;21:88-94.
9. McCormick PA, Biagini MR, Dick R, et al. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study. Hepatology 1992;16:1180-6.
10. Mastai R, Bosch J, Navasa M, et al. Effect of continous infusion and bolus injections of somatostatin (SMT) on azygous blood flow and hepatic and systemic hemodynamics in patients with portal hypertension, comparison with vasopressin. J Hepatol 1986;3:S53.
11. Eriksson LS, Wahren J. Intravenous and subcutaneous administration of a long-acting somatostatin analogue: effects on glucose metabolism and splanchnic haemodynamics in healthy subjects. Eur J Clin Invest 1989;19:213-9.
12. Hanisch E, Doertenbach J, Usadel KH. Somatostatin in acute bleeding oesophageal varices. Pharmacology and rationale for use. Drugs 1992;44(Suppl 2):24-35,70-2.
13. Sonnenberg GE, Keller U, Perruchoud A, Burckhardt D, Gyr K. Effect of somatostatin on splanchnic hemodynamics in patients with cirrhosis of the liver and in normal subjects. Gastroenterology 1981;80:526-32.